The Cluster brings together 215 innovative companies specializing in the development of innovative medicines, medical diagnostic and treatment products, new bio-compatible materials and cellular technology products.

The companies have already created over 1300 jobs. The Cluster’s startups generated total revenue of  1 bln RUR for last 12 months.

The Cluster has given financial support for more than 80 projects R&D.

Cluster’s residents have been highly successful in their research and development efforts

  • Patent No. 2435783 ‘Chimera Peptide and Pharmaceutical Composition for the Treatment of Cancerous Conditions’ issued to Skolkovo resident MetaMax was included in the top 100 Russian inventions of 2011, with the list published by the Federal Service for Intellectual Property (Russian Patent Service).
  • The findings of research carried out by OncoMax were presented at the Best Oral Presentations session of the 5th European Multidisciplinary symposium for urological cancers (EMUC) that was held in Marseilles on November 15-17, 2013.
  • In 2011, Russia’s first ever Prix Galien Award in the Best Research nomination was given to Alexander Sobolev and Andrey Rosenkrantz from the Institute of Gene Biology of the Russian Academy of Sciences and Vladimir Lunin (Gamaleya Epidemiology and Microbiology Research Institute) for the Modular Nano-transporter Technology (MNT) they are working on. MNT can repeatedly increase the efficacy of drugs. Skolkovo-based company Translek founded in 2011 is working on the commercialization of this technology.
  • Hemacore Labs has developed a laboratory prototype of a device and technology for Thrombodynamics-4D analysis (a new integrated, high-sensitivity hemostasis test that can easily detect disorders of both plasma- and platelet-mediated stages of blood clotting); a series of experiments were successfully carried out and the results were presented in an oral presentation at the ISTH-2011 congress (Dashkevich et al, 2011); an article was published (Dashkevich et al, 2012) and was praised by the editorial staff of Stern magazine (2012).
  • Eidos-Medicine has developed a series of robotic surgery simulators and successfully sold its first Surgery Simulator to the US-based corporation Covidien, one of the largest global manufacturers of medical equipment, in 2014.
  • In March 2014, Fusion Pharma formed the first advisory board in Germany to address the clinical development of a new candidate drug for the treatment of drug resistant forms of chronic myelogenous leukemia, while at the 2nd congress of Russian hematologists held in Moscow in April 2014 the company presented its findings to the international scientific community. The congress participants were extremely happy to hear that a breakthrough drug could be just around the corner. Doctors are in urgent need of a new highly effective and safe drug for the treatment of this condition.
  • Another Cluster resident Incuron, LLC got an FDA approval in 2013 for the clinical trials of the new cancer drug CBL0137. The company successfully completed phase 1a trials in one year and is now enrolling patients for Phase 1b trials in the USA.
  • Skolkovo resident 3D Bioprinting Solutions opened a laboratory in Moscow that is implementing an innovative project to develop 3D organ bio-printing. The company was founded by the Independent Laboratory Invitro.
  • NovaMedica Innotech, LLC announced the creation of the research center in the Skolkovo Technopark to contribute to the transfer of pharmaceutical products and technologies to Russia as well as to its in-house research and development.
  • In February 2014, Bind (RUS) opened a new R&D center in Moscow. The company’s laboratories are going to develop targeted drugs that utilize nano-particles for the treatment of cancers and other conditions.
  • At the world’s largest fundamental cancer research congress organized by the American Association of Cancer Research held in San Diego on April 5-9, 2014, Russian Pharmaceutical Technologies presented the first results of pre-clinical trials of the new cancer drug RPT835. There was a keen interest at the congress in the new RPT835 inhibitor